Detail page

Knowledge Web

Person

Till Milde (1973-)

Kinderarzt

Name	Till Milde
Time	1973- (Date of birth and death)
Place	Heidelberg (Wirkungsort) Jena (Wirkungsort) Deutschland
Gender	männlich
Academic degree	Prof. Dr. med.
Profession	Kinderarzt (characteristic profession)
Variant	T. Milde
Related	Klinik für Kinder- und Jugendmedizin Jena Universitätsklinikum Jena Klinikum Heidelberg Kinderheilkunde (Thema) Onkologie (Thema)
Further information	Dissertation, Universität Lübeck, 2004 Pädiatrische Hämatologie und Onkologie am Zentrum für Kinder- und Jugendmedizin der Universität Heidelberg
Record type	Person
GND-Identifier	1038311837
Record ID	1038311837
Involved in show all Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells MOST wanted: navigating the MAPK-OIS-SASP-tumor microenvironment axis in primary pediatric low-grade glioma and preclinical models Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow Group-specific cellular metabolism in Medulloblastoma Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas The role of key pharmacodynamic and pharmacokinetic parameters in drug response prediction of pediatric tumors in the precision oncology study INFORM Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry : A Unique and Challenging Population Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population Local and systemic therapy of recurrent medulloblastomas in children and adolescents: results of the P-HIT-REZ 2005 study GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types A study of regulatory challenges of paediatric oncology phase I/II trial submissions and guidance on protocol development INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features The whole-genome landscape of medulloblastoma subtypes Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance Risk stratification of childhood medulloblastoma in the molecular era: the current consensus New brain tumor entities emerge from molecular classification of CNS-PNETs Next-generation personalised medicine for high-risk paediatric cancer patients – the INFORM pilot study Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma or Leukemia Dissecting the genomic complexity underlying medulloblastoma A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Till Milde (1973-)

Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours

Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells

MOST wanted: navigating the MAPK-OIS-SASP-tumor microenvironment axis in primary pediatric low-grade glioma and preclinical models

Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines

Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort

Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow

Group-specific cellular metabolism in Medulloblastoma

Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification

MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas

The role of key pharmacodynamic and pharmacokinetic parameters in drug response prediction of pediatric tumors in the precision oncology study INFORM

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts

Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification

Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival

Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome

Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM

Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry : A Unique and Challenging Population

Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population

Local and systemic therapy of recurrent medulloblastomas in children and adolescents: results of the P-HIT-REZ 2005 study

GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types

A study of regulatory challenges of paediatric oncology phase I/II trial submissions and guidance on protocol development

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions

Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience

Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations

Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features

The whole-genome landscape of medulloblastoma subtypes

Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance

Risk stratification of childhood medulloblastoma in the molecular era: the current consensus

New brain tumor entities emerge from molecular classification of CNS-PNETs

Next-generation personalised medicine for high-risk paediatric cancer patients – the INFORM pilot study

Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma

Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets

Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma or Leukemia

Dissecting the genomic complexity underlying medulloblastoma

A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat